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Background. Multiple myeloma (MM) and its therapies may induce a severely compromised humoral immunity. We have
performed a longitudinal analysis of IgG-antibody responses against inﬂuenza virus (FLU) and tetanus toxoid (TT) as surrogate
markers for the B cell-mediated immunity in MM patients. Methods. 1094 serum samples of 190MM patients and samples from
100 healthy donors were analyzed by ELISA for FLU- and TT-speciﬁc antibodies. Results. MM patients evidenced lower levels of
FLU- and TT-speciﬁc antibodies than healthy controls (P<0.001). Immunoreactivity decreased with progressing disease and
worsening clinical status. Levels of FLU- and TT-speciﬁc antibodies increased shortly (0-6 months) after alloSCT (P<0.001), a
time-period during which intravenous immunoglobulin (IVIG) is routinely applied. Thereafter, antibody concentrations declined
and remained suppressed for 3 years in the case of FLU-speciﬁc and for more than 5 years in the case of TT-speciﬁc antibodies.
Conclusions. We found that MM is associated with a profound disease- and therapy-related immunosuppression, which is
compensated for a few months after alloSCT, most likely by application of IVIG. This and the diﬀerences regarding the recovery
of anti-FLU and anti-TT antibody titers during the following years need to be taken into account for optimizing IVIG application
and immunization after alloSCT.
1.Introduction
Multiple myeloma (MM) is a disease arising from a malig-
nant plasma cell clone proliferating in the bone marrow
(BM) [1]. On the one hand, the growing tumor mass leads
to a reduction of normal hematopoiesis, and, secondly,
myeloma cells create a cytokine/chemokine microenviron-
ment favoring the malignant phenotype while suppressing
local and systemic immunity [2]. Both factors contribute
to the profound immune dysregulation present in myeloma
patients [3]. MM patients evidence phenotypic and func-
tional defects of humoral as well as cellular immunity. Par-
ticularly B-cell responses are altered to a state of functional
hypogammaglobulinemia, leading to an increased risk for
opportunistic infections in MM patients [3]. As a conse-
quence of the impaired protective immunity against bacteria
and viruses, infections represent a major cause of death in
MM patients [4]. The administration of intravenous im-
munoglobulin (IVIG) has been used to temporarily restore
antibody-mediated immunity, in particular after high-dose2 Clinical and Developmental Immunology
chemotherapy [5]. However, it is unknown to what extent
and for how long the passively transferred humoral immu-
nity compensates the severe disease- and therapy-related
immunosuppression in myeloma patients.
As MM itself is dependent on the suppression and dys-
regulation of the adaptive immune response, the develop-
ment of diﬀerent modes of immunotherapy seems an attrac-
tive option for improving treatment of myeloma patients.
Allogeneic stem cell transplantation is one of the most
promising ways to restore the ability of the immune system
to recognize and destroy MM cells [6]. The transfer of a
healthy,donor-derivedimmunesystem,whichisnottolerant
to the malignant plasma cell clone, is currently the only
potentially curative approach for MM patients [6]. The
immunological graft-versus-myeloma eﬀect (GvM) is pow-
erful, but it comes along with a signiﬁcant risk of developing
a graft-versus-host reaction (GvHD), which represents a
potentially deadly threat often requiring strong prophylactic
(and sometimes therapeutic) immunosuppression [6, 7].
Optimized strategies are needed to determine exactly how
much immunosuppression is needed to dampen harmful
alloimmune reactions while still allowing for clinically
required graft-versus-myeloma eﬀects [7].
In order to improve our understanding of the therapy-
and disease-related defects in the humoral immunity of
myeloma patients, antibody responses need to be assessed
repeatedlyduringthecourseofthedisease.Memoryimmune
responses induced by routine vaccinations or natural expo-
sure, like the ones directed against inﬂuenza virus (FLU) and
tetanus toxoid (TT), can serve as markers for the general
immune competence of the patient at a given time point
[8, 9]. Surprisingly, data on the longitudinal behavior of
immune responses to such common antigens are scarce
and have not been systematically addressed in MM patients
[10, 11], in particular not after alloSCT. Here, we have
performed the largest longitudinal analysis of FLU- and TT-
speciﬁc antibody responses in MM patients to evaluate the
consequences of the malignancy itself as well as of diﬀerent
modes of therapy on humoral immunity.
2.MaterialandMethods
2.1. Patients. Patients were admitted for diagnostic purposes
and/or treatment to the University Medical Center Ham-
burg-Eppendorf. Repeated blood samples were obtained
during routine diagnostic procedures, and all participants
provided informed consent prior to sample collection. A
total of 1094 peripheral blood (PB) plasma samples were
collected from 194 consecutive MM patients. In addition,
100 PB sera were obtained from healthy donors. Samples
were collected as previously described [12, 13]. Patients
were included between December 2004 and February 2008.
All patients were diagnosed and treated for MM. None
of the patients had received new agents such as borte-
zomib, lenalidomide, or thalidomide. AutoSCT was gener-
ally performed twice in a tandem setting. Induction treat-
ment for alloSCT routinely comprised 140mg/m2 melpha-
lan, 150mg/m2 ﬂudarabine, and 30–60mg anti-thymocyte
globulin per kg. Peripheral hematopoietic grafts were used
for transplantation and cyclosporine A (until day 180) and
mycophenolate mofetil (until day 54) were used as GVHD
prophylaxis. No patient received consolidation or mainte-
nance treatment. Only single patients received sporadically
received donor lymphocyte infusions. All patients received
i.v. immunoglobulins on day 1, 7, 14, 21, 28, 54, and 86 after
alloSCT.BoostervaccineswereappliedoneyearafteralloSCT
for FLU and TT, respectively.
This study was conducted in accordance with the decla-
ration of Helsinki. The protocol had received approval by the
local ethics committee (decision number OB-038/06).
2.2. Proteins and Peptides. Recombinant inﬂuenza nucle-
oprotein (FLU) produced in E. coli was obtained from
Imgenex (San Diego, CA, USA) and tetanus toxoid (TT) was
provided by Chiron Behring (Marburg, Germany). Control
protein for FLU and TT antibody detection was GST ex-
pressed in E. coli (Cell Systems, St. Katharinen, Germany).
2.3. Enzyme-Linked Immunosorbent Assay (ELISA). ELISA
was performed as previously described [13]. For all samples,
the GST background value was subtracted from the FLU- or
TT-speciﬁc OD at 405nm.
2.4. Statistical Analysis. Statistical analyses were performed
using GraphPad software. To avoid bias by repeated sam-
pling, samples were stratiﬁed according to the time frame
during which they were sampled (e.g., before alloSCT or
3 months after alloSCT) and a mean value was calculated
for all samples of a given patient collected within a given
time frame. In a second step, these values were used to
determine the mean for the respective group of patients
(i.e., all myeloma patients per time frame) as suggested
by Bland and Altman [14, 15]. The Mann-Whitney U test
was used to calculate diﬀerences between diﬀerent patient
cohorts. Analysis of covariance was used to assess correla-
tions between FLU- and TT-speciﬁc antibodies. Correlations
between clinicopathological variables and FLU- or TT-
speciﬁc antibodies were determined by Pearson’s χ2 test. All
tests were performed as univariate analyses. Diﬀerences were
regarded signiﬁcant if P<0.05.
3. Results
3.1. Myeloma Patients Evidence Reduced Levels of FLU- and
TT-Speciﬁc IgG Antibodies Compared to Healthy Controls.
Over a time course of 4 years, a total of 194 consecutive
MM patients were included into this study, and from the
respective patients, 1094 PB samples were collected. A mean
number of 5.4 (range 1–47) serum samples were collected
per patient during a median follow-up period of 11.4
months (range 1–39 months). Most patients were included
at advanced stages of the disease (mainly stage II and III
according to the Salmon and Durie classiﬁcation), and all
but 10 patients had received chemotherapy, autologous stem
cell transplantation (autoSCT), or alloSCT, respectively, as
maximum therapy prior to study inclusion (see Table 1 for
patient characteristics).Clinical and Developmental Immunology 3
Table 1: Patient characteristics. Data are shown for all patients. LC:
light chain, HC: heavy chain. §indicates missing information for
some patients.
Parameter Total
Sex
Male 115
Female 75
Age
> 60 69
≤ 60 121
Karyotype
Normal 83
Complex 15
del13q14 46
del17p13 12
t (4; 14) 9
Not tested 25
LC isotype
Light lambda 62
Light kappa 100
HC isotype§
IgG 167
IgA 18
Maximum treatment
Untreated 10
Chemotherapy 81
autoSCT 30
alloSCT 74
Stage∗,#,§
I3 2
II 52
III 95
∗One patient was found to bear a 13q14 and a 17p13 deletion.
#Stage according to the Salmon and Durie classiﬁcation.
When we compared levels of IgG antibodies directed
against FLU or TT between myeloma patients and healthy
donors (N = 100), we found both types of humoral
responses to be signiﬁcantly reduced in the patients
(Figure 1(a)). To address if the FLU- and TT-speciﬁc anti-
bodies reﬂected the general humoral capacity of the given
group of subjects to a comparable extent, we performed
correlational analyses. Indeed, we observed that levels of
FLU- and TT-speciﬁc IgG antibodies correlated positively
and highly signiﬁcantly in patients as well as those in the
groupofdonors(Figure 1(b)).Thisﬁndingfurtherindicated
that a state of general immunosuppression was present in the
patients, irrespective of the nature of the given antigen. It
is important to note, however, that myeloma patients were
compared to unselected, anonymized blood donors and that
we, therefore, cannot rule out that diﬀerences observed were
partly related to confounding factors, that is, the median age
o fe a c hg r o u po fs u b j e c t s .
3.2. FLU and TT Speciﬁc Antibodies Show a Transient Increase
Followed by a Long-Lasting Suppression after AlloSCT. Since
both alloSCT and autoSCT are known to have signiﬁcantly
impact on the immune capacity of the patient, we asked how
IgG antibody responses against FLU and TT are inﬂuenced
by each type of transplantation. Only such patients were
included in this analysis who had either received autoSCT or
alloSCT as maximum therapy. When we monitored levels of
FLU- and TT-speciﬁc antibodies before and after autoSCT,
we did not ﬁnd any major changes during the follow-up
period when compared to pretransplant values (Figure 2).
In contrast, both FLU and TT antibodies signiﬁcantly in-
creased during the ﬁrst three months after alloSCT to a
level comparable to healthy donors. Thereafter, humoral
responsesdeclinedsigniﬁcantlyandremainedsuppressedfor
3 and more than 5 years in the case of FLU- and TT-speciﬁc
antibodies, respectively.
To analyze the inﬂuence of alloSCT on humoral immu-
nity against FLU and TT in a more detailed manner, we
selected a cohort of patients of whom we had been able
to obtain samples during the last 6 months before alloSCT
and the ﬁrst 6 months after alloSCT. Comparing levels
of FLU- and TT-speciﬁc antibodies for this homogenous
collective at both time points, we conﬁrmed our observation
of a signiﬁcant increase following alloSCT (Figure 3(a)). In
contrast,nosigniﬁcantchangewasfoundwhenwecompared
the same time points in a group of patients who had received
autoSCT (Figure 3(a)). Next we compared samples of the
same patients, collected at time points equal 6 months or
lessafteralloSCTwithsamplescollectedmorethan6months
after alloSCT. We were able to demonstrate that 6 months
represent an important cutoﬀ with regard to the humoral
immunity of MM patients after alloSCT (Figure 3(b)). In
contrast no diﬀerence in FLU- or TT-speciﬁc antibodies was
found when autoSCT patients were monitored over the same
period of time (data not shown).
3.3. Levels of FLU and TT Antibodies Correlate Negatively
with Markers of Poor Prognosis in MM. As a next step, we
correlated FLU and TT antibody levels with a large variety
of clinicopathological measures (Table 2). For FLU-speciﬁc
antibodies, the only statistically signiﬁcant association was
found for concentrations of total IgG in IgG myeloma with
lower IgG concentration being associated with elevated anti-
FLU antibody levels (Table 2). On the other hand, higher
levels of TT-speciﬁc antibodies were signiﬁcantly associated
with younger age (<60 years) and normal serum calcium
and albumin as well as normal IgG concentrations in IgG
myeloma. Overall, these associations suggest that general
immunoreactivity decreases with progressing disease and
worsening clinical status of the patient.
4. Discussion
Analyzing the largest cohort of MM patients to date for
the presence of FLU- and TT-speciﬁc antibodies, we found
myeloma patients to evidence signiﬁcantly reduced levels of
antibodies against both antigens. MM patients are known4 Clinical and Developmental Immunology
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Figure 1: Comparison of levels of FLU- and TT-speciﬁc antibodies in MM patients compared to healthy donors. (a) Mean values for FLU-
and TT-speciﬁc speciﬁc antibodies for HD (n = 100) and MM patients (N = 190). OD 405nm of the background control GST was
subtracted for each sample. Asterisks indicate signiﬁcant diﬀerences (∗∗∗P<0.001) between groups. (b) Correlational analysis of FLU- and
TT-speciﬁc antibodies in HD (N = 100) and MM patients (N = 190).
to be deﬁcient in polyclonal immunoglobulins [16]. Upon
vaccination MM patients show a delayed increase in IgM,
a quicker shift to IgG and lower titers of antibodies against
the target antigen [17]. The general B-cell dysfunction in
myeloma patients results in antibody titers below protective
levels, rendering MM patients more susceptible to infections
despite vaccination [3, 18]. Levels of FLU- and TT-speciﬁc
antibodies have been investigated in small cohorts of MM
patients, mostly revealing lower antibody titers in MM
than in healthy controls [18–21]. In our large longitudinal
study, we were able to conﬁrm these results and we believe
that these reduced levels of antibodies against two selected
targets indeed reﬂect the negative impact of the malignancy
and previous therapies on the humoral (and probably
also cellular) immunity in myeloma patients. This idea
would also be supported by our observation of a negative
correlation between TT- and/or FLU-speciﬁc antibody levels
and markers of a poor prognosis in MM such as paraprotein
levels and concentrations of serum calcium and albumin as
well as the patient’s age.
In addition to the aforementioned parameters we de-
tected a strong inﬂuence of alloSCT on the levels of TT-
and FLU-speciﬁc IgG antibodies in myeloma patients.
We observed elevated antibody levels during the ﬁrst 6
months after alloSCT followed by a suppression of humoral
immunity for up to 5 years and more. Treatments such as
chemotherapy, autoSCT, and alloSCT have previously been
shown to signiﬁcantly inﬂuence the immune system of
cancerpatients[9,10,22,23].InMM,smallstudieshavesug-
gested alloSCT to impair the humoral immune response, but
little is known about the time course of this suppression, and
data on ideal time points for vaccination are controversialClinical and Developmental Immunology 5
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Figure 2: Time course of FLU- and TT-speciﬁc antibodies in MM patients undergoing alloSCT. Samples harvested in the frame of allo-
and autoSCT were sorted according to time after transplantation. Only those patients were included into this analysis who had alloSCT or
autoSCT, as maximum therapy. For the samples collected in the frame of alloSCT the group numbers of samples per time point were as
follows: 30, 24, 24, 18, 19, 45, 33, and 20. For the samples collected in the frame of alloSCT, the group numbers of samples per time point
were as follows: 25, 21, 10, 10, 4, 18, 2, and 2. Asterisks indicate signiﬁcant diﬀerences when compared to the time point “3 months” after
SCT (∗∗P<0.01 and ∗∗∗P<0.001).
[11, 24]. In our current study, we were able to demonstrate
that, as in other diseases requiring alloSCT, immunity to
FLU and TT decreases over time following transplantation,
most likely as a surrogate marker of prolonged immunosup-
pression [25]. On the other hand, we also found a transient
increase of FLU and TT antibodies in the ﬁrst 6 months
following alloSCT. While there are a number of possible
explanations for this increase, we believe that it is most likely
caused by intravenous substitution with polyclonal intra-
venous immunoglobulins (IVIGs) commonly performed at
our center during the ﬁrst months post transplantation [26].
This hypothesis would be consistent with previous studies
describing large amounts of both FLU- and TT-speciﬁc
antibodies as parts of IVIG preparations [27].
Another interesting observation we have made in our
current analysis is that, following the initial ampliﬁcation
of humoral immune responses against TT and NP, antibody
levels were suppressed for at least 3 years in the case of FLU-
speciﬁc immunity while TT-speciﬁc antibodies remained
below early post-alloSCT (<6 months) levels for the whole
remaining observation period. There are four possible
explanations for the discrepancies in the behavior of both
antibody speciﬁcities. First, based on the fact that FLU-
speciﬁc immunity is often acquired spontaneously while TT-
speciﬁc humoral responses are always generated by vaccina-
tion, that repeated natural exposures to inﬂuenza antigen
may have boosted the antibody response [8, 18]. On the
other hand, TT-speciﬁc vaccination may have less stringently
been performed than FLU-speciﬁc vaccination because, in
contrast to inﬂuenza infections, tetanus infections are not a
leading cause of mortality in MM patients. This hypothesis is
least likely to ﬁt, since at our institutions, TT antibodies are
routinely monitored and low titers lead to repeated booster
vaccinations. Third, Ek et al. have previously reported that in6 Clinical and Developmental Immunology
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Figure 3: Time-dependent impact of alloSCT on FLU- and TT-speciﬁc antibodies in selected patients. (a) Comparison of FLU and TT
antibodies 6 months before and 6 months after alloSCT and autoSCT. For 21 alloSCT patients and for 14 autoSCT patients, samples had
beencollectedforbothofthesetimepoints.DiﬀerencesweresigniﬁcantwithP<0.001forFLU-antibodiesbeforeandafteralloSCTandwith
P<0.0001 for TT antibodies before and after alloSCT. No signiﬁcant diﬀerences were found between FLU and TT antibody concentrations
before and after autoSCT. (b) Comparison of FLU and TT antibodies collected less than 6 months after alloSCT and more than 6 months
after alloSCT. Samples had been collected from 20 alloSCT patients at both time points. Diﬀerences in antibody titers were signiﬁcant in the
case of anti-FLU (P<0.01) and anti-TT antibodies (P<0.0001).Clinical and Developmental Immunology 7
Table 2: correlation of FLU-antibodies and TT-antibodies with clinical parameters.
Parameter Stratiﬁcation N Mean (FLU) Mean (TT)
Gender men 115 1,042 1,202
women 75 0,918 1,133
Age
≤ 60 years 122 0,969 1,253
∗
> 60 years 67 1,034 1,023
∗
Hemoglobin low 157 1,022 1,181
normal 30 0,859 1,087
Albumin <35g/l 27 0,877 0,699
∗
≥35g/l 158 1,015 1,247
∗
LDH
≤225 U/I 137 1,007 1,156
>225 U/I 49 0,972 1,194
Calcium
≤2,63mmol/l 182 0,995 1,145
∗
>2,63mmol/l 2 1,040 2,470
∗
Creatinin
≤1,3mg/dL 146 0,990 1,123
>1,3mg/dL 37 1,035 1,355
IgG (for IgG myeloma)
≤16g/l 44 1,018 1,248
∗
>16g/l 41 0,746 0,874
∗
IgG (for IgA myeloma)
≤16g/l 39 0,994 1,103
>16g/l 4 0,883 0,870
IgA (for IgA myeloma)
≤4g/l 17 0,986 1,151
>4g/l 26 0,982 1,034
Kappa-light chains
≤3,7g/l 14 1,116 1,557
>3,7g/l 0 — —
Lambda-light chain
≤2g/l 12 1,164 1,007
>2g/l 1 0,210 0,030
Deletion 13q14 positive 46 0,900 1,014
negative 117 1,038 1,218
Deletion 17p13 positive 13 1,058 1,350
negative 150 0,989 1,142
Translocation t (4; 14) positive 9 0,933 0,793
negative 153 0,998 1,178
β2-Microglobulin
≤3mg/l 60 0,970 1,200
>3mg/l 32 0,807 0,942
GvHD positive 42 0,885 0,965
negative 21 0,893 1,172
Plasma cells in BM
≤10% 68 0,978 1,241
>10% 37 0,949 1,006
∗indicates a statistically signiﬁcant result (P<0.05); if not otherwise speciﬁed, diﬀerences between groups are not signiﬁcant.
leukemia patients levels of TT- but not Haemophilus inﬂuen-
zae-speciﬁc antibodies correlated negatively with disease
recurrence and were less protective in these immunosup-
pressed patients [8] indicating that the extent of treatment-
induced humoral immunosuppression might indeed depend
on the type of the given antigen [8]. Accordingly, it has
previously been described that antiviral antibody responses
were more stable with a half-life of up to 50 years compared
to 10 years for antibacterial responses, that is, against TT
[28]. We, therefore, believe that the latter concept is most
likely to explain the diﬀerent time-frames until recovery of
TT- and NP-speciﬁc antibodies after alloSCT.8 Clinical and Developmental Immunology
Overall, our current ﬁndings support the concept that
MM is associated with a profound disease- and therapy-
related immunosuppression which is compensated for a
few months after alloSCT by the application of intravenous
immunoglobulin. This and the fundamental diﬀerences
regarding the recovery of anti-FLU and anti-TT antibody
titers during the following years need to be taken into ac-
count for optimizing strategies for IVIG application and
active immunization after alloSCT.
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